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Glossary
Absorption-The transport of a chemical from the outer surface of the skin into both the skin and systemic circulation (including penetration, permeation, and resorption).
Acute exposure-Contact with a chemical that occurs once or for only a short period of time.
Cancer-Any one of a group of diseases that occurs when cells in the body become abnormal and grow or multiply out of control.
Contaminant-A chemical that is (1) unintentionally present within a neat substance or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen and present within a neat substance or mixture at a concentration less than 0.1%.
Cutaneous (or percutaneous)-Referring to the skin (or through the skin).
Dermal-Referring to the skin.
Dermal contact-Contact with (touching) the skin.
Direct effects-Localized, non-immune-mediated adverse health effects on the skin, including corrosion, primary irritation, changes in skin pigmentation, and reduction/disruption of the skin barrier integrity, occurring at or near the point of contact with chemicals.
Immune-mediated responses-Responses mediated by the immune system, including allergic responses.
Sensitization-A specific immune-mediated response that develops following exposure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis (ACD) or other immune-mediated diseases such as asthma, depending on the site and route of re-exposure. Substance-A chemical. 
Systemic effects-Systemic

Purpose
This skin notation profile presents (1) a brief summary of epidemiological and toxicological data associated with skin contact with 1-BP and (2) the rationale behind the hazard-specific skin notation (SK) assignment for 1-BP. The SK assignment is based on the scientific rationale and logic outlined in the Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009 ]. The summarized information and health hazard assessment are limited to an evaluation of the potential health effects of dermal exposure to 1-BP and the potential for direct skin injuries from 1-BP. A literature search was conducted through January 2013 to identify 1-BP toxicokinetics, acute toxicity, repeated-dose systemic toxicity, carcinogenicity, biological system/function-specific effects (including reproductive and developmental effects and immunotoxicity), irritation, and sensitization. Information was considered from studies of humans, animals, or appropriate modeling systems that are relevant to assessing the effects of dermal exposure to 1-BP. 
Overview of SK Assignment for 1-Bromopropane
1-Bromopropane is potentially capable of causing numerous adverse health effects following skin contact. A critical review of available data has resulted in the following SK assignment for 1-BP: SK: SYS-DIR (IRR). Table 1 provides an overview of the critical effects and data used to develop the SK assignment for 1-BP. 
Systemic Toxicity from Skin Exposure (SK: SYS)
There were no toxicokinetic studies involving humans identified; however an in vitro dermal penetration study was identified. Frasch et al. [2011] used heat-separated epidermal membranes from Caucasian female breasts or abdominal skin samples with 3 different dosing regimens. The skin samples were dosed with 10 microliters per square centimeter (µL/cm 2 ), equivalent to 13.5 milligrams per square centimeter (mg/cm 2 ), in an non occluded environment to simulate splash exposures; had a transient exposure where 1-BP was applied to donor compartments in an occluded environment, and then removed after 10 minutes of exposure with the skin surfaces wiped to remove excess 1-BP; or were exposed to an infinite dose of 1-BP in an occluded environment for 3 hours [Frasch et al. 2011] . The authors noted that the total amount of 1-BP absorbed from the 13.5 mg/cm 2 dose was 22 µg/cm 2 , corresponding to an average penetration of 0.16% of the applied dose [Frasch et al. 2011] . The total amount of 1-BP absorbed from transient and infinite exposures was 179 µg/cm 2 , and 1,322 µg/cm 2 , respectively [Frasch et al. 2011] . These data indicate that 1-BP has the potential for substantial dermal penetration dependent of type and duration of exposure. The potential of 1-BP to pose a skin absorption hazard has also been evaluated with use of a predictive algorithm for estimating and evaluating the health hazards of dermal exposure to chemical substances [NIOSH 2009 ]. The evaluation method compares the chemical dose accumulated in the body from skin absorption and the dose from respiratory absorption during the same period. The ratio of the skin dose to the inhalation dose (SI ratio) calculated for 1-BP by this alternative method was 17.02. An SI ratio of ≥0.1 indicates that skin absorption may significantly contribute to the overall body burden of a substance [NIOSH 2009]; therefore, 1-BP is considered to be absorbed through the skin following dermal exposure. Additional information on the SI ratio can be found in the appendix.
No dermal lethal doses (LD Lo ) of 1-BP for humans have been identified. Only one acute dermal toxicity study was identified, in which 1-BP (2,000 milligrams per kilogram body weight [mg/kg]; 99.3% purity) was applied to the shaved dorsal skin of rats under semi-occlusive wrap for 24 hours [Elf Atochem 1995a] . In this study, no clinical signs of toxicity were observed, and the authors concluded that the dermal LD 50 (the dose resulting in 50% mortality in the exposed population) was higher than 2,000 mg/kg, indicating that 1-BP is not acutely toxic upon dermal expsoure. However, 1-BP is highly volatile, and the use of semi-occlusive instead of occlusive wrap is likely to have resulted in evaporation of the chemical, leading to a less-than-optimal exposure period.
Because of a paucity of toxicokinetic and toxicity data concerning skin exposures to 1-BP, a review of data associated with alternative exposure pathways (e.g., inhalation, oral, and subcutaneous injections) was conducted. Numerous studies of rats revealed systemic effects, including neurotoxicity, hepatotoxicity, hematotoxicity, reproductive toxicity, and developmental toxicity, attributed to the inhalation of airborne 1-BP below 1,000 parts per million (ppm) [ClinTrials Bioresearch 1997; Ichihara et al. 2000a, b; WIL Research Laboratories 2001; Wang et al. 2002 Wang et al. , 2003 Yamada et al. 2003; NTP 2004; Banu et al. 2007; Fueta et al. 2007] . Anderson et al. [2010] reported significant decreases in the spleen IgM responses to sheep red blood cells in mice (125-500 ppm) and rats (1000 ppm) after whole body inhalation exposure to 1-BP for 10 weeks. Lee et al. [2005, 2007] treated mice with a single dose of 1-BP at levels of 200, 500, and 1,000 mg/kg via the oral route. At 500-and 1000-mg/kg treatment levels, the authors reported a significant increase in relative liver weight and changes in liver enzyme levels [Lee et al. 2005 [Lee et al. , 2007 . In another investigation, Zhao et al. [1999] treated rats with daily injections of 1-BP at treatment levels of 3.7 millimoles (mmol)/kg (corresponding to 455 mg/kg) and 11.0 mmol/kg (corresponding to 1,353 mg/kg) for 20 days. At both treatment levels, neurotoxic effects were reported. There were no human epidemiological studies or repeated-dose (subchronic or chronic) studies in animals that evaluated the potential of 1-BP to cause systemic toxicity following dermal exposure identified. However, occupational (presumably a combination of dermal and respiratory) exposure to 1-BP resulted in neuropathy in a male worker after he was exposed for 2 months to a degreasing solvent (containing 95.5% 1-BP, less than 0.5% butylene oxide, less than 2.5% 1,3-dioxolane, and less than 0.25% nitromethane) [Sclar 1999 ]. In addition, central nervous system effects were noted in a cohort of workers who had sprayed an adhesive (containing 70% 1-BP, 0.3% 1,2-epoxybutane, 10% styrene-butadiene rubber, and 20% rosin ester) without proper personal protective equipment in a poorly ventilated area for 30 to 40 hours a week for 3 months [Beck and Caravati 2003] . Other case reports also detailed nervous system effects [Ichihara et al. 2002 [Ichihara et al. , 2004a [Ichihara et al. , 2004b Majersik et al. 2007; Raymond and Ford 2007] . Hanley et al. [2006] assessed occupational exposures to 1-BP through air sampling and urinary testing for bromide (Br -) concentrations (a known biomarker of 1-BP exposure) in workers employed as either adhesive sprayers or nonsprayers at foam-fabricating plants that used a spray adhesive 4
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containing within 1-BP during the manufacture of polyurethane seat cushions. One of the reported findings included a lower than expected correlation between urinary Br -concentration and time-weighted average (TWA) for sprayers. The authors stated that this disparity may be due to the absorption of 1-BP by the skin when the sprayers handled the wet adhesive with bare hands. The results of Hanley et al. [2006] indicate that 1-BP may be absorbed via the skin, thus contributing to the systemic dose.
No standard toxicity or specialty studies evaluating biological system/function-specific effects (including reproductive and developmental effects and immunotoxicity) following dermal exposure to 1-BP were identified. Table 2 summarizes the carcinogenic designations for 1-BP from NIOSH and other governmental and nongovernmental organizations. [2014] Reasonably anticipated to be a human carcinogen European Parliament [2008] No GHS designation USEPA [2015] No designation IARC [2012] No designation ACGIH [2014] A3, Confirmed animal carcinogen with unknown relevance to humans Although the mathematical model predicted that 1-BP was not readily absorbed by the skin, there was an in vitro dermal penetration study identified that indicates that 1-BP has the potential for substantial dermal penetration dependent on type and duration of exposure [Frasch et al. 2011] . Studies of workers exposed to 1-BP indicate that the solvent may be absorbed by the skin and contribute to systemic toxicity, but the results of these investigations are confounded by the inhalation of 1-BP vapors [Sclar 1999; Ichihara et al. 2002 Ichihara et al. , 2004a Ichihara et al. , 2004b Beck and Caravati 2003; NTP 2004; Hanley et al. 2006; Majersik et al. 2007; Raymond and Ford 2007] . A review of animal toxicity data from several non-dermal exposure routes indicated that 1-BP is capable of inducing a range of systemic effects, including neurotoxicity, hepatotoxicity, hematotoxicity, reproductive toxicity, and developmental toxicity in a dose-response manner [ClinTrials 
Direct Effects on Skin (SK: DIR)
No evidence of skin corrosivity of 1-BP, no in vitro tests for corrosivity in human or animal skin models, and no in vitro tests of skin integrity using cadaver skin were identified. Frasch et al. [2011] evaluated the corrosivity of 1-BP using the EpiDerm human reconstructed epidermis model. Using this model, a chemical is classified as corrosive to skin if the cell viability after a 3 minute exposure is less than 50% and less than 15% after a one hour exposure [Frasch et al. 2011] . Frasch et al. [2011] found that after the 3 minute exposure, the viability for cells exposed to 1-BP was 101% compared to the water-exposed control and a one hour exposure of 1-BP had a cell viability of 22%, indicating that 1-BP is not considered corrosive to the skin. No studies on the skin-irritating potential of 1-BP in humans were identified, but there is limited evidence that the substance is a skin irritant in animals. Using a Draize scale, Jacobs et al. [1987] reported 1-BP was a skin irritant, and observed a limit concentration (defined as the highest tested concentration at which the mean erythema score remains below 2) for skin irritation of 50% for 1-BP solution in sweet almond oil in rabbits. In another test, performed according to the chemical testing guidelines of the Organization for Economic Co-operation and Development (OECD), topical application of 1-BP to rabbit skin produced erythema and edema and complete regeneration of the skin occurred within 8 days [Pálovics 2004] . Pálovics [2004] also tested the irritation potential of 1-BP on the chorioallantoic membrane of hen's egg according to the ECVAM/INVITTIX Protocol. In this test, local application of 1-BP caused copious hemorrhage and moderate lysis of blood vessels in the chorioallantoic membrane, indicating severe irritation after exposure to 1-BP; however, this procedure is typically used to evaluate ocular irritancy. Although rats administered 2,000 mg/kg 1-BP covered by a semi-occlusive dressing for 24 hours exhibited no cutaneous reaction [Elf Atochem 1995a] , use of the semi-occlusive rather than occlusive wrap in this study was likely to result in less-than-optimal exposure. This may explain the lack of irritation observed by those investigators. The structure-activity relationship model (Deductive Estimation of Risk from Existing Knowledge, or DEREK, for Windows) predicted 1-BP to be negative for skin irritation.
A study using the EpiDerm human reconstructed epidermis model [Frasch et al. 2011] 
Immune-mediated Responses (SK: SEN)
No diagnostic human patch tests that evaluated the potential of 1-BP to cause skin sensitization were identified. However, one study evaluated the skin sensitization potential of 1-BP with use of the guinea pig maximization test. In this study, Elf Atochem [1995b] intradermally injected 0.1 ml of 1-BP solution at a concentration of 25% on day 1, and applied 0.5ml of 1-BP in occlusive conditions to the skin of guinea pigs for 48 hours on day 8. A challenge dose of 0.5 ml 1-BP was given on day 12 on the left flank in occlusive conditions for 24 hours [Elf Atochem 1995b] . The investigators did not observe any cutaneous reactions that can be attributed to the sensitization potential of 1-BP [Elf Atochem 1995b] . DEREK predicted 1-BP to have skin sensitization potential. However, because of the absence of human data and insufficient animal data, a skin notation of SK: SEN is not assigned to 1-BP.
Summary
Although the mathematical model predicted that 1-BP was not readily absorbed by the skin, there was an in vitro dermal penetration study identified that indicates that 1-BP has the potential for substantial dermal penetration dependent of type and duration of exposure [Frasch et al. 2011] . A review of the available literature indicates that 1-BP is capable of inducing a wide array of adverse systemic health effects, including neurotoxicity, hepatotoxicity, hematotoxicity, reproductive toxicity, and developmental toxicity, regardless of exposure route Although the exact systemic hazards associated with skin contact and absorption of 1-BP are unknown, 1-BP is assigned the SK: SYS notation; this notation is based on the recognition of adverse health effects in test animals exposed via the inhalation, oral, and subcutaneous injection routes. Although a study using the EpiDerm human reconstructed epidermis model [Frasch et al. 2011] indicated that 1-BP is not corrosive to the skin following exposure to 1-BP, two in vivo tests, conducted with standard methods [Jacobs et al. 1987 2 ; Pálovics 2004], provide limited evidence that 1-BP is irritating to the skin of rabbits. Although no human patch tests that evaluated the sensitization potential of 1-BP were identified, one guinea pig maximization test [Elf Atochem 1995b] showed that the substance is not a skin sensitizer. Therefore, on the basis of this assessment, 1-BP is assigned the composite skin notation SK: SYS-DIR (IRR). Table A1 summarizes the data applied in the previously described equations to determine the SI ratio for 1-BP. The calculated SI ratio was 8.43. On the basis of these results, 1-BP is predicted to represent a skin absorption hazard. The OEL used in calculation of the SI ratio for 1-BP was the ACGIH threshold limit value (TLV) [ACGIH 2014 ].
Calculation
